Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Using The Molecular Classification Of Glioblastoma To Inform Personalized Treatment

Adriana Olar, K. Aldape
Published 2014 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Glioblastoma is the most common and most aggressive diffuse glioma, associated with short survival and uniformly fatal outcome, irrespective of treatment. It is characterized by morphological, genetic and gene‐expression heterogeneity. The current standard of treatment is maximal surgical resection, followed by radiation, with concurrent and adjuvant chemotherapy. Due to the heterogeneity, most tumours develop resistance to treatment and shortly recur. Following recurrence, glioblastoma is quickly fatal in the majority of cases. Recent genetic molecular advances have contributed to a better understanding of glioblastoma pathophysiology and disease stratification. In this paper we review basic glioblastoma pathophysiology, with emphasis on clinically relevant genetic molecular alterations and potential targets for further drug development. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
This paper references
10.1007/s11060-013-1073-y
Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age
S. Ha (2013)
10.1200/JCO.2009.21.9832
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
M. Sanson (2009)
10.1093/JNEN/64.6.479
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
H. Ohgaki (2005)
10.1016/j.cancergencyto.2008.09.017
Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity.
C. Franco-Hernández (2009)
10.1016/j.stem.2011.04.013
Deadly teamwork: neural cancer stem cells and the tumor microenvironment.
J. Lathia (2011)
10.1007/s00401-010-0781-z
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
C. Hartmann (2010)
10.1186/1471-2407-13-299
Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial
Maria Teresa Solomón (2012)
10.1016/j.ijrobp.2010.01.070
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
J. Uhm (2011)
10.1186/1476-4598-10-128
Chemoresistance of glioblastoma cancer stem cells - much more complex than expected
D. Beier (2011)
10.1002/cncr.21819
Prognostic impact of molecular markers in a series of 220 primary glioblastomas
C. Houillier (2006)
10.1158/1078-0432.CCR-09-0715
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
S. Nobusawa (2009)
10.1016/S0513-5117(10)79302-9
The transcriptional network for mesenchymal transformation of brain tumours
J. Uhm (2010)
10.3892/IJO.28.6.1531
Effective silencing of EGFR with RNAi demonstrates non-EGFR dependent proliferation of glioma cells.
A. Vollmann (2006)
10.1007/s00109-010-0683-5
Ras regulates interleukin-1β-induced HIF-1α transcriptional activity in glioblastoma
V. Sharma (2010)
10.1007/s11060-012-0875-7
p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells
Y. T. Yeung (2012)
Identification of a cancer stem cell in human brain tumors.
S. Singh (2003)
10.1038/nature07205
Cancer-related inflammation
A. Mantovani (2008)
WHO Classification of Tumors of the Central Nervous System
DN Louis (2007)
10.1093/JNCI/93.16.1246
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.
J. Smith (2001)
10.1093/neuonc/nos218
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.
T. A. Dolecek (2012)
10.1007/s10014-011-0077-6
Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation
S. Takano (2011)
10.1093/neuonc/nop050
O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications.
A. Brandes (2010)
10.1186/1476-4598-5-67
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
G. Liu (2006)
10.1073/pnas.1016030108
Transdifferentiation of glioblastoma cells into vascular endothelial cells
Yasushi Soda (2011)
10.1038/nature09624
Glioblastoma stem-like cells give rise to tumour endothelium
Rong Wang (2010)
10.1158/1078-0432.CCR-0841-3
Age-Dependent Prognostic Effects of Genetic Alterations in Glioblastoma
T. Batchelor (2004)
10.1371/journal.pone.0065444
Screening for EGFR Amplifications with a Novel Method and Their Significance for the Outcome of Glioblastoma Patients
M. Bieńkowski (2013)
10.1200/JCO.2008.19.8721
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
H. Friedman (2009)
10.1007/s00401-010-0647-4
Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing
J. Felsberg (2010)
10.1073/pnas.0700118104
Dose-dependent cross-talk between the transforming growth factor-β and interleukin-1 signaling pathways
Tao Lu (2007)
10.1097/00005072-200606000-00001
'Pseudopalisading' Necrosis in Glioblastoma: A Familiar Morphologic Feature That Links Vascular Pathology, Hypoxia, and Angiogenesis
Yuan Rong (2006)
10.1111/bpa.12018
Glioblastoma with Oligodendroglioma Component (GBM‐O): Molecular Genetic and Clinical Characteristics
C. Appin (2013)
10.1111/j.1440-1789.2009.01081.x
Primary glioblastomas with and without EGFR amplification: Relationship to genetic alterations and clinicopathological features
R. Benito (2010)
10.1158/0008-5472.CAN-04-1364
Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma
R. Galli (2004)
10.1200/JCO.2008.18.0612
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
P. Brown (2008)
10.1002/path.2995
Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers
S. Yip (2012)
10.1038/nrneurol.2009.197
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller (2010)
10.1200/JCO.2010.30.2729
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
A. Lai (2011)
10.2353/AJPATH.2007.070011
Genetic pathways to primary and secondary glioblastoma.
H. Ohgaki (2007)
10.1016/J.DNAREP.2007.03.008
MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.
B. Kaina (2007)
Temozolomide (Temodar).
S. Bruce (2001)
10.1093/neuonc/nop015
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
J. Raizer (2010)
10.1016/j.ccr.2009.12.020
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
R. Verhaak (2010)
10.1007/s00401-011-0938-4
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial
M. Hegi (2011)
10.1056/NEJMOA043331
MGMT gene silencing and benefit from temozolomide in glioblastoma.
M. Hegi (2005)
10.1038/sj.onc.1207183
Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer
T. Nakagawachi (2003)
10.1126/science.1164382
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
D. Parsons (2008)
10.1056/NEJMOA043330
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
R. Stupp (2005)
10.1097/NEN.0b013e3181c391be
Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues
C. Horbinski (2009)
10.1097/00005072-199812000-00005
Chromosome 7 rearrangements in glioblastomas; loci adjacent to EGFR are independently amplified.
L. Liu (1998)
10.1111/j.1750-3639.2008.00153.x
Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker *
M. Preusser (2008)
10.1038/nature09734
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
L. Ricci‐Vitiani (2011)
Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo.
A. Ekstrand (1991)
10.1172/JCI32278
ErbB receptors: from oncogenes to targeted cancer therapies.
H. Zhang (2007)
10.1073/PNAS.91.16.7727
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
R. Nishikawa (1994)
10.1007/s10014-012-0090-4
Molecular pathogenesis of IDH mutations in gliomas
K. Ichimura (2012)
10.1101/gad.176800.111
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma.
K. Bhat (2011)
Genetic pathways to glioblastoma: a population-based study
H Ohgaki (2004)
10.1016/j.anndiagpath.2011.08.010
Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.
Adriana Olar (2012)
Phase III Trial of bevacizumab added to standard radiotherapy and temozolomide for newlydiagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in Avaglio
O Chinot (2012)
Clinical Practice Guidelines in Oncology
N. NCC (2013)
A restricted cell population propagates glioblastoma growth after chemotherapy
J. Chen (2012)
10.1093/CARCIN/22.10.1715
Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene.
M. Nakamura (2001)
10.1007/s11060-011-0594-5
Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis
R. Olson (2011)
10.1038/nature07385
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
R. McLendon (2008)
10.1073/PNAS.87.21.8602
Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas.
N. Sugawa (1990)
10.1038/onc.2011.563
EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway
R. Bonavia (2012)
10.1097/PAS.0b013e3182518e12
Paradoxical Relationship Between the Degree of EGFR Amplification and Outcome in Glioblastomas
Jonathan Hobbs (2012)
10.1212/01.wnl.0000400061.70034.aa
Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome
G. Kaloshi (2011)
10.1212/WNL.0b013e318239ba7c
Neural Stem/Progenitors and Glioma Stem-Like Cells Have Differential Sensitivity to Chemotherapy
M. Chamberlain (2011)
10.1200/JCO.2008.17.5984
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
M. J. van den Bent (2009)
10.1007/s10014-011-0029-1
Genetic profile of astrocytic and oligodendroglial gliomas
H. Ohgaki (2011)
Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
J. Xiong (2010)
Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.
A. Fabi (2009)
10.1128/MCB.16.9.4604
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.
J. Forsythe (1996)
10.1093/neuonc/nop073
Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors.
B. J. Scott (2010)
10.1038/nrd2137
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery
B. S. Zhou (2009)
10.1007/s00401-012-1011-7
Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas
B. Ellezam (2012)
10.1016/S1474-4422(10)70105-8
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers
M. Jansen (2010)
10.1111/bph.12008
Interleukins in glioblastoma pathophysiology: implications for therapy
Y. T. Yeung (2013)
10.1016/j.ccr.2013.08.001
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.
K. Bhat (2013)
10.1200/JCO.2009.23.6497
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
W. Wick (2009)
10.1002/glia.21165
Molecular subclassification of diffuse gliomas: Seeing order in the chaos
J. Huse (2011)
10.1158/1078-0432.CCR-09-2902
IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
M. J. van den Bent (2010)
10.1126/science.1236062
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
D. Rohle (2013)
10.2353/ajpath.2009.080958
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
Takuya Watanabe (2009)
10.1016/S1470-2045(09)70025-7
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
R. Stupp (2009)
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
N. Shinojima (2003)
10.1007/s00401-007-0243-4
The 2007 WHO Classification of Tumours of the Central Nervous System
D. N. Louis (2007)
10.1002/cncr.21221
The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years
A. Korshunov (2005)
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
L. Frederick (2000)
10.1158/1078-0432.CCR-08-0644
Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme
R. Pallini (2008)
10.1016/j.ajpath.2012.01.040
The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma.
L. Cooper (2012)
10.1074/jbc.M704205200
Epidermal Growth Factor Plays a Crucial Role in Mitogenic Regulation of Human Brain Tumor Stem Cells*
A. Soeda (2008)
10.1093/neuonc/noq033
Bevacizumab in recurrent high-grade pediatric gliomas.
A. Narayana (2010)
10.1055/S-2006-933341
Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy.
J. Rak (2006)
10.1158/0008-5472.CAN-03-2073
Pseudopalisades in Glioblastoma Are Hypoxic, Express Extracellular Matrix Proteases, and Are Formed by an Actively Migrating Cell Population
D. Brat (2004)
10.1093/neuonc/nop027
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
J. D. de Groot (2010)
10.1002/ijc.27385
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
G. Reifenberger (2012)
10.1371/journal.pone.0024807
Direct In Vivo Evidence for Tumor Propagation by Glioblastoma Cancer Stem Cells
J. Lathia (2011)
IDH1 and IDH2 mutations in gliomas.
F. Ducray (2009)
10.1158/1535-7163.MCT-11-0048
Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
M. Hegi (2011)
10.1200/JCO.2009.26.7252
Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.
Barbara S. Paugh (2010)
10.1007/s00381-010-1214-y
MGMT gene promoter methylation in pediatric glioblastomas
Arti Srivastava (2010)
10.1093/neuonc/nor232
Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome.
Y. Wang (2012)
10.1212/WNL.0b013e3181e1cf3a
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
M. Labussière (2010)
10.1002/pbc.20803
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma
A. Donson (2007)
Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients.
M. Simmons (2001)
10.1200/JCO.2009.23.0805
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
M. Weller (2009)
10.1007/s00381-010-1264-1
IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group
I. Pollack (2010)
10.1093/neuonc/nop020
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
A. Rivera (2010)
10.1200/JCO.2007.14.8163
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
A. Brandes (2008)
10.1007/s00401-008-0455-2
Analysis of the IDH1 codon 132 mutation in brain tumors
J. Balss (2008)
10.1158/0008-5472.CAN-04-3376
PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma.
Yuan Rong (2005)
10.1126/science.1220834
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Devendra Singh (2012)
10.1054/bjoc.2001.1942
IL-6 gene amplification and expression in human glioblastomas
A. Tchirkov (2001)
10.1158/1078-0432.CCR-11-1274
A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951
M. J. van den Bent (2011)
10.1016/J.CCR.2006.02.019
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.
H. Phillips (2006)
10.1093/neuonc/nou223
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.
Q. Ostrom (2014)
10.18632/ONCOTARGET.588
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Y. Jiao (2012)
10.1215/15228517-2009-025
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
K. Ichimura (2009)
10.1097/PAI.0b013e31802fac2f
MGMT Immunohistochemical Expression and Promoter Methylation in Human Glioblastoma
F. Rodriguez (2008)
10.1111/j.1349-7006.2009.01270.x
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients
Y. Sonoda (2009)
10.1371/journal.pone.0012548
The Proneural Molecular Signature Is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse Gliomas
L. Cooper (2010)
10.1101/gad.1890510
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.
María-del-Mar Inda (2010)
10.1158/1078-0432.CCR-03-0384
Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide
M. Hegi (2004)
10.1038/nrc3023
CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?
M. Zöller (2011)
10.1097/00006123-199912000-00034
Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
M. Feldkamp (1999)
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
M. Mrugala (2009)
10.1158/1078-0432.CCR-06-2184
Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival
M. Eoli (2007)
10.1038/nature03128
Identification of human brain tumour initiating cells
S. Singh (2004)
10.1007/s00401-009-0561-9
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
C. Hartmann (2009)
10.1097/PPO.0b013e31818d8178
Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.
G. Cairncross (2008)
10.1007/s00401-013-1130-9
Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors
P. Mur (2013)
10.1002/ijc.26083
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
J. Felsberg (2011)
10.1002/IJC.2910620206
EGFR gene amplification ‐ rearrangement in human glioblastomas
K. Schwechheimer (1995)
10.1002/glia.10094
Human cortical glial tumors contain neural stem‐like cells expressing astroglial and neuronal markers in vitro
T. Ignatova (2002)
10.1038/nature05236
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
S. Bao (2006)
10.1593/NEO.111338
Expression of EGFRvIII in glioblastoma: prognostic significance revisited.
N. Montano (2011)
10.1007/s13402-011-0034-8
Glioblastomas with oligodendroglial component-common origin of the different histological parts and genetic subclassification
B. Klink (2011)
10.1227/NEU.0b013e3181f743f5
O6-Methylguanine DNA Methyltransferase Gene Promoter Methylation Status in Gliomas and Its Correlation With Other Molecular Alterations: First Indian Report With Review of Challenges for Use in Customized Treatment
Prerana Jha (2010)
10.1016/j.ccr.2010.03.017
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
H. Noushmehr (2010)
10.1371/journal.pone.0023332
The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma
F. Ohka (2011)
10.3109/07357907.2010.483506
Cetuximab Insufficiently Inhibits Glioma Cell Growth Due to Persistent EGFR Downstream Signaling
Benedikte Hasselbalch (2010)
10.1158/1078-0432.CCR-12-1557
Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition
Y. Piao (2013)
10.1097/PPO.0b013e3182431c57
Studying a complex tumor: potential and pitfalls.
S. Zheng (2012)
10.1038/sj.bjc.6603586
Interleukin-6 gene amplification and shortened survival in glioblastoma patients
A. Tchirkov (2007)
10.1007/s11060-011-0787-y
MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors
M. Mellai (2011)
10.3174/ajnr.A2397
Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma
L. C. Hygino da Cruz (2011)
10.1016/J.YNEU.2012.05.008
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
J. Uhm (2012)
10.1016/S1077-9108(09)79438-1
Malignant Astrocytomas Originate from Neural Stem/Progenitor Cells in a Somatic Tumor Suppressor Mouse Model
H. Armah (2010)



This paper is referenced by
10.1186/s40170-020-00215-8
Glutamine uptake and utilization of human mesenchymal glioblastoma in orthotopic mouse model
Kristell Oizel (2020)
10.1016/j.ccell.2017.06.003
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.
Qianghu Wang (2017)
10.3390/ijms18122732
Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma
A. Arbab (2017)
10.3978/j.issn.2305-5839.2015.03.57
Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification.
K. Vigneswaran (2015)
10.1186/s12885-019-6280-2
System-based approaches as prognostic tools for glioblastoma
M. Salvucci (2019)
10.4135/9781483381411.n341
A meta-analysis
Jing-Nan Hu (2013)
10.1080/15384101.2017.1361062
Harnessing OLIG2 function in tumorigenicity and plasticity to target malignant gliomas
J. Kosty (2017)
10.21873/cgp.20085
Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the SGK1 Gene Are Associated with Poorer Survival
S. Lehrer (2018)
10.1007/s13277-015-4519-3
Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells
C. Biray Avci (2015)
Nanoparticle based strategies for the treatment of Glioblastoma
F. Fisusi (2014)
10.18632/ONCOTARGET.2745
EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas
N. Pérez-Janices (2015)
10.3389/fonc.2014.00047
Prognostic and Predictive Biomarkers in Adult and Pediatric Gliomas: Toward Personalized Treatment
H. Haynes (2014)
10.1021/acschemneuro.7b00197
Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials.
A. Barrette (2018)
10.4172/1948-5956.1000410
Anti-VEGFR2 driven nuclear translocation of VEGFR2 and acquired malignant hallmarks are mutation dependent in glioblastoma.
A. Shankar (2016)
PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth.
R. An (2019)
10.1016/j.nic.2014.09.006
Genomics of brain tumor imaging.
W. Pope (2015)
10.1073/pnas.1511694112
Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord
Yuxuan Wang (2015)
10.1089/cbr.2018.2758
Genomics-Guided Immunotherapy for Precision Medicine in Cancer.
S. Mukherjee (2019)
10.11591/ijeecs.v18.i1.pp343-350
Functional analysis of cancer gene subtype from co-clustering and classification
Logenthiran Machap (2020)
10.1042/BST20150064
The 18-kDa mitochondrial translocator protein in gliomas: from the bench to bedside.
K. Janczar (2015)
10.1186/s40880-019-0351-2
Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial
Lin Kong (2019)
10.1016/j.ccell.2018.03.020
A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment.
A. Griveau (2018)
10.1007/s00401-018-1842-y
Reconstructing the molecular life history of gliomas
F. Barthel (2018)
10.1093/noajnl/vdaa123
Impact of anesthesia and analgesia techniques on glioblastoma progression. A narrative review
Ann Privorotskiy (2020)
10.1101/052076
Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment
Qianghu Wang (2016)
10.1021/acschemneuro.6b00251
Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells.
S. Daniele (2017)
10.1002/jcb.29440
LncRNA‐XIST/microRNA‐126 sponge mediates cell proliferation and glucose metabolism through the IRS1/PI3K/Akt pathway in glioma
Zhihua Cheng (2019)
10.1042/BSR20181051
Inhibition of microRNA-299-5p sensitizes glioblastoma cells to temozolomide via the MAPK/ERK signaling pathway
Yujiang Peng (2018)
10.1016/j.bbrc.2017.03.032
ALG2 regulates glioblastoma cell proliferation, migration and tumorigenicity.
Dunke Zhang (2017)
10.1007/s12253-017-0311-6
Molecular Subgroups of Glioblastoma– an Assessment by Immunohistochemical Markers
Ádám Nagy (2017)
10.1053/j.seminoncol.2014.09.008
Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy.
A. Kanner (2014)
10.3389/fonc.2018.00123
Epstein–Barr Virus in Gliomas: Cause, Association, or Artifact?
S. Akhtar (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar